Kynam Capital Management, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001907884
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 32 positions · Total reported value $1.81B · Top-10 concentration 72.7% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 48.8% · 4 new · 7 cut · 9 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +14.0% · vs SPY -0.8% · Prev Value $1.55B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, Kynam Capital Management, LP disclosed 32 equity positions with a combined reported value of $1.81B. The filing implies a focused portfolio: its ten largest positions account for 72.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were CLDX ($198.07M), SNDX ($175.99M), PCVX ($169.88M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+5.7pp) and away from Other (-5.7pp).
Versus the prior quarter, Kynam Capital Management, LP opened 4 new positions, trimmed 7 and fully exited 9, a turnover rate of 48.8% of positions. The portfolio's overlap with the prior quarter was 68% of names.
The largest new positions opened in Q2 2026 were SMMT ($17.48M), INSM ($10.66M), PBLS ($6.84M).
Of the 9 positions fully exited versus the prior quarter, the largest were KALV ($36.66M), APLS ($33.19M), RVMD ($20.18M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
Fully Exited (vs previous quarter)
- KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $36.66M
- APLS APELLIS PHARMACEUTICALS INC · prev qtr: $33.19M
- RVMD REVOLUTION MEDICINES INC COM · prev qtr: $20.18M
- SLNO SOLENO THERAPEUTICS INC · prev qtr: $18.75M
- EVMN EVOMMUNE INC · prev qtr: $14.38M
- DSGN DESIGN THERAPEUTICS INC · prev qtr: $8.35M
- WVE WAVE LIFE SCIENCES INC · prev qtr: $7.00M
- CLYM CLIMB BIO INC · prev qtr: $6.87M
Insider Transactions (Form 4)
Latest Kynam Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Kynam Capital Management, LP files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 32 positions worth $1.81B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- SEC registration: 801-126187 (status: Approved), registered 2022-07-22
- Regulatory AUM (Form ADV): $2.41B as of 2026-04-10
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
Portfolio Structure
- 32 positions · $1.81B reported value (Q2 2026)
- Top 10 holdings = 72.7% of reported value
- Largest position: CLDX (CELLDEX THERAPEUTICS INC NEW) at 10.9%
- Average position size: $56.54M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 4 new, 12 added, 7 reduced, 9 exited
- 9 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
5.32M | $198.07M | 10.95% | Reduce | |
| 2 |
|
8.05M | $175.99M | 9.73% | Hold | |
| 3 |
|
2.92M | $169.88M | 9.39% | Hold | |
| 4 |
|
3.67M | $141.92M | 7.84% | Reduce | |
| 5 |
|
2.89M | $124.01M | 6.85% | Reduce | |
| 6 |
|
6.45M | $118.56M | 6.55% | Add | |
| 7 |
|
2.00M | $113.62M | 6.28% | Add | |
| 8 |
|
2.84M | $97.50M | 5.39% | Reduce | |
| 9 |
|
2.43M | $89.58M | 4.95% | Add | |
| 10 |
|
3.00M | $86.67M | 4.79% | Add | |
| 11 |
|
21.70M | $81.39M | 4.50% | Add | |
| 12 |
|
3.30M | $61.74M | 3.41% | Add | |
| 13 |
|
3.11M | $56.71M | 3.13% | Hold | |
| 14 |
|
934.80K | $51.60M | 2.85% | Hold | |
| 15 |
|
1.38M | $43.66M | 2.41% | Add | |
| 16 |
|
1.19M | $28.98M | 1.60% | Hold | |
| 17 |
|
872.56K | $28.97M | 1.60% | Hold | |
| 18 |
|
2.52M | $25.23M | 1.39% | Reduce | |
| 19 |
|
661.79K | $22.88M | 1.26% | Add | |
| 20 |
|
1.20M | $17.48M | 0.97% | New | |
| 21 |
|
2.42M | $12.87M | 0.71% | Add | |
| 22 |
|
100.00K | $10.66M | 0.59% | New | |
| 23 |
|
1.24M | $10.52M | 0.58% | Add | |
| 24 |
|
6.84M | $8.75M | 0.48% | Hold | |
| 25 |
|
532.98K | $8.50M | 0.47% | Add | |
| 26 |
|
3.81M | $7.66M | 0.42% | Add | |
| 27 |
|
250.00K | $6.84M | 0.38% | New | |
| 28 |
|
2.50M | $4.41M | 0.24% | Hold | |
| 29 |
|
1.57M | $2.91M | 0.16% | Hold | |
| 30 |
|
96.74K | $996.43K | 0.06% | Reduce | |
| 31 |
|
457.86K | $792.09K | 0.04% | Reduce | |
| 32 |
|
84.40K | $71.17K | 0.00% | New | |
Loading forecast…
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q2)
P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)
Historical Backtest (10 quarters)
Avg precision 81% · recall 81% · F1 81% · avg rank error 2.0 · Top-10 turnover 20%
| Quarter | Prec. | Recall | F1 | Predicted Top 10 | Actual Top 10 |
|---|---|---|---|---|---|
| 2024-Q1 | 70% | 70% | 70% | NTRA · SNDX · CLDX · PCVX · VERA · PTGX · IMGN · MOR · COGT · LQDA | NTRA · SNDX · CLDX · VERA · COGT · DVAX · PCVX · VRTX · LQDA · BCRX |
| 2024-Q2 | 80% | 80% | 80% | NTRA · SNDX · CLDX · COGT · VERA · DVAX · PCVX · VRTX · BCRX · LQDA | NTRA · VRTX · CLDX · SNDX · SPY · DVAX · COGT · INSM · PCVX · VERA |
| 2024-Q3 | 70% | 70% | 70% | NTRA · VRTX · CLDX · SNDX · SPY · DVAX · COGT · INSM · BCRX · PCVX | NTRA · PCVX · CLDX · SNDX · COGT · DVAX · VERA · BCRX · CGON · VRDN |
| 2024-Q4 | 90% | 90% | 90% | NTRA · PCVX · CLDX · SNDX · DVAX · COGT · CGON · BCRX · VERA · VRDN | NTRA · PCVX · SPY · CLDX · SNDX · DVAX · CGON · COGT · BCRX · VRDN |
| 2025-Q1 | 80% | 80% | 80% | NTRA · PCVX · SPY · CLDX · SNDX · DVAX · CGON · COGT · VRDN · BCRX | NTRA · PCVX · CLDX · SNDX · BCRX · CGON · VRDN · VERA · COGT · IMCR |
| 2025-Q2 | 90% | 90% | 90% | NTRA · PCVX · CLDX · SNDX · VRDN · CGON · BCRX · VERA · IMCR · COGT | CLDX · PCVX · VERA · SNDX · BCRX · CGON · VRDN · COGT · BEAM · IMCR |
| 2025-Q3 | 100% | 100% | 100% | CLDX · PCVX · VERA · SNDX · BCRX · VRDN · CGON · COGT · BEAM · IMCR | CLDX · SNDX · VERA · COGT · PCVX · VRDN · CGON · BCRX · BEAM · IMCR |
| 2025-Q4 | 80% | 80% | 80% | CLDX · SNDX · VERA · COGT · PCVX · VRDN · CGON · BCRX · BEAM · IMCR | COGT · VERA · SNDX · CLDX · PCVX · BCRX · VRDN · TYRA · CGON · CTMX |
| 2026-Q1 | 80% | 80% | 80% | COGT · VERA · SNDX · CLDX · PCVX · BCRX · CTMX · VRDN · NRIX · TYRA | SNDX · CLDX · PCVX · COGT · VERA · BEAM · CTMX · BCRX · VRDN · CGEM |
| 2026-Q2 ★ | 70% | 70% | 70% | SNDX · CLDX · PCVX · COGT · VERA · BEAM · CTMX · BCRX · CGEM · URGN | CLDX · SNDX · PCVX · COGT · VERA · VRDN · TVTX · BEAM · URGN · LEGN |
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
FAQ
What did Kynam Capital Management, LP buy in 2026-Q2?
In its 2026-Q2 13F filing, Kynam Capital Management, LP reported 32 equity positions worth $1.81B in aggregate; its largest disclosed positions were CLDX ($198.07M), SNDX ($175.99M), PCVX ($169.88M).
How large is Kynam Capital Management, LP's portfolio?
Kynam Capital Management, LP reported $1.81B of long equity holdings across 32 positions as of 2026-Q2. Top-10 holdings account for 72.7% of reported value.
What is Kynam Capital Management, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.